WO2009092276A1 - 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 - Google Patents
双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- WO2009092276A1 WO2009092276A1 PCT/CN2009/000001 CN2009000001W WO2009092276A1 WO 2009092276 A1 WO2009092276 A1 WO 2009092276A1 CN 2009000001 W CN2009000001 W CN 2009000001W WO 2009092276 A1 WO2009092276 A1 WO 2009092276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mmol
- carboxylic acid
- group
- methyl
- added
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D231/08—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen or sulfur atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to a novel bicyclic substituted pyrazolone azo derivative of the formula (I), a process for the preparation thereof, and a pharmaceutical composition containing the same, and as a therapeutic agent, particularly thrombopoietin (TPC simulation) And their use as thrombopoietin receptor agonists.
- TPO Thrombopoietin
- the activity of TPO is derived from the binding of TPO to the TPO receptor (also known as MPL).
- TPO receptor also known as MPL.
- the TPO receptor has been successfully cloned and sequenced for amino acid sequence (Vigon et al., Proc. Nat. Acad. ScL 89: 5640-5644 (1992))
- TPO is a 332-amino acid glycosylated polypeptide that plays a key role in regulating megakaryocyte production and platelet production by bone marrow megakaryocytes (Kuter et al., Proc. Nat. Acad. Sci. USA 91 : 1 1104-1 1 108 (1994); Barley et al., Cell 77: 1117-1 124 (1994); Kaushansky et al., Nature 369: 568-571 (1994); Wendling et al., Nature 369: 571- 574 (1994); and Sauvage et al., Nature 369: 533-538 (1994)). TPO is produced in the liver but mainly acts on the bone marrow, stimulating stem cell differentiation.
- TPO is a major regulator of thrombocytopenia and a large number of studies on increasing platelet count, size, and increasing the involvement of experimental animal isotope in platelets (Metcalf Nature 369:519-520 (1994)).
- TPO has been used to diagnose and treat a variety of blood diseases, such as those caused primarily by platelet defects.
- TPO can be used to treat thrombocytopenia, especially chemotherapy, radiation and bone marrow transplantation for the treatment of cancer and lymphoma.
- the thrombopoietin analog dtrombopag is reported by GSK in the patent (WO-00189457/WO-01089457/WO-2006064957) and exhibits considerable activity.
- the present invention discloses a series of compounds that are more effective as TPO receptor agonists and are potent TPO mimetics. Summary of the invention
- A is selected from a carbon atom or an oxygen atom
- R is selected from a hydrogen atom or an alkyl group
- R, . R 2 and each independently selected from a hydrogen atom, a fluorenyl group, an alkoxy group, a halogen, an 'aryl group or a heteroaryl group, wherein the aryl or heteroaryl group is optionally further selected from one or more selected from one or more Substituted with a substituent of a mercapto group, a halogen, a hydroxyl group, a tetrazolyl group, an imidazole, a dihydroimidazole, a carboxylic acid or a carboxylic acid ester;
- R 5 and R 7 are each independently selected from a hydrogen atom, a decyl group, an alkoxy group, a halogen, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxylic acid or a carboxylic acid ester;
- R is selected from a hydrogen atom or a sulfhydryl group
- aryl or heteroaryl group wherein the aryl or heteroaryl group is optionally further selected from one or more selected from the group consisting of fluorenyl, halogen, hydroxy, tetrazolyl, imidazole, dihydroimidazole, carboxylic acid or carboxylic acid ester Substituted by a substituent;
- R 2 , R 3 and R 4 are each independently selected from a hydrogen atom, a decyl group, an alkoxy group or a halogen;
- R 5 and R 7 are each independently selected from a hydrogen atom, a decyl group, an alkoxy group, a halogen, a hydroxyl group, an amino group, a nitro group, a cyano group, a carboxylic acid or a carboxylic acid ester;
- R s , R 9 , . And R n are each independently selected from a hydrogen atom or an alkyl group
- n 0, 1 or 2.
- Preferred compounds of the compounds of the formula (I) of the present invention include, but are not limited to:
- the present invention includes a compound represented by the formula (IA) which is an intermediate for the synthesis of the compound of the formula (I):
- A is selected from a carbon atom or an oxygen atom
- R s , R 9 , R IG and R n are each independently selected from a hydrogen atom or a fluorenyl group
- n 0, 1 or 2.
- Preferred compounds of the compound of the formula (IA) of the present invention include, but are not limited to:
- the amino-substituted benzopolycyclic ring is diazotized with sodium nitrite in an acidic solution, and then reduced by stannous chloride to obtain hydrazine, hydrazine and an electrophilic carbonyl compound such as ethyl acetoacetate in a suitable solvent ( Condensation under heating, such as acetic acid, ethanol, etc., gives the compound of formula (IA).
- another aspect of the present invention provides a process for the preparation of the compound (I) of the formula, which comprises:
- a substituted aniline compound By diazotizing a substituted aniline compound with sodium nitrite in a suitable acidic solution (such as nitric acid, sulfuric acid, hydrochloric acid), and then reacting a compound of the formula (IA) with an alkaline solution (such as sodium hydrogencarbonate, carbonic acid) A coupling reaction occurs in potassium hydrogen) to give a compound of the formula ⁇ .
- a suitable acidic solution such as nitric acid, sulfuric acid, hydrochloric acid
- an alkaline solution such as sodium hydrogencarbonate, carbonic acid
- the present invention relates to the use of a compound of the formula and ( ⁇ ) in the manufacture of a medicament for the treatment of thrombocytopenia.
- a therapeutically effective amount of a drug selected from the group consisting of: colony stimulating factor, cytokine, chemokine, interleukin or cytokine receptor agonist or antagonist, soluble receptor, receptor agonist or antagonist
- a drug selected from the group consisting of: colony stimulating factor, cytokine, chemokine, interleukin or cytokine receptor agonist or antagonist, soluble receptor, receptor agonist or antagonist
- An antibody or a peptide or small molecule that functions in the same mechanism as one or more of the drugs.
- the present invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising a pharmaceutically effective amount of a compound of the formula ⁇ and ( ⁇ ), and a pharmaceutically acceptable salt, hydrate or solvate thereof, and a pharmaceutically acceptable salt.
- the composition may further comprise a therapeutically effective amount of a drug selected from the group consisting of: a colony stimulating factor, a cytokine, a chemokine, an interleukin or a cytokine receptor agonist.
- a drug selected from the group consisting of: a colony stimulating factor, a cytokine, a chemokine, an interleukin or a cytokine receptor agonist.
- the combined use includes the simultaneous use or sequential use of the compounds described herein.
- the present invention relates to a method of preparing a pharmaceutical composition
- a pharmaceutically acceptable carrier or diluent and an effective amount of a compound of the formula ⁇ and ( ⁇ ) and a pharmaceutically acceptable salt, hydrate or solvate thereof, the method comprising
- the compounds of formula (I) and ( ⁇ ) are combined with a pharmaceutically acceptable carrier and diluent.
- Alkyl means a saturated aliphatic hydrocarbon group comprising straight and branched chain groups of 1 to 20 carbon atoms.
- An alkyl group having 1 to 10 carbon atoms such as a methyl group, an ethyl group, a propyl group, a 2-propyl group, a n-butyl group, an isobutyl group, a t-butyl group or a pentyl group or the like is preferable.
- lower fluorenyl groups having 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl or t-butyl groups and the like.
- the fluorenyl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more, independently selected from the group consisting of an indenyl group, a decyloxy group, a halogen group, a hydroxyl group, an amino group, a nitro group, a cyano group, and an aryl group. , heteroaryl, carboxylic acid or carboxylic acid ester.
- Aryl means a group having at least one aromatic ring structure, that is, an aromatic ring having a conjugated ⁇ -electron system, Carbocyclic aryl, heteroaryl and biaryl.
- the block group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more, independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, aryl. , heteroaryl, carboxylic acid or carboxylic acid ester.
- Heteroaryl means an aryl group having from 1 to 4 heteroatoms as ring atoms, the remaining ring atoms being carbon, and hetero atoms including oxygen, sulfur and nitrogen.
- the ring may be a 5- or 6-membered ring.
- the heteroaryl group include a furyl group, a thienyl group, a pyridyl group, a pyrrole, an N-fluorenylpyrrolyl group, a pyrimidinyl group, a pyrazinyl group, an imidazolyl group, a tetrazolyl group and the like.
- the heteroaryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more, independently selected from the group consisting of alkyl, alkoxy, halogen, hydroxy, amino, nitro, cyano, aryl.
- Base heteroaryl, carboxylic acid or carboxylic acid ester.
- Haldroxy means an -OH group.
- Alkoxy means -0-(alkyl) and -0-(unsubstituted cycloalkyl). Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy and the like.
- the methoxy group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more, independently selected from the group consisting of an indenyl group, a decyloxy group, a halogen group, a hydroxyl group, an amino group, a nitro group, a cyano group, and an aromatic group.
- Base heteroaryl, carboxylic acid or carboxylic acid ester.
- Halogen means fluoro, chloro, bromo or iodo.
- Amino means -NH 2 .
- Neitro means -N0 2 .
- Alkoxy means -0-(alkyl).
- the amino-substituted benzopolycyclic ring is diazotized with sodium nitrite in an acidic solution, and then reduced by stannous chloride to obtain hydrazine, hydrazine and an electrophilic carbonyl compound such as ethyl acetoacetate in a suitable solvent (such as acetic acid, Ethanol or the like is condensed under heating to give a compound of the formula (IA).
- the substituted o-bromophenol is nitrated by sodium nitrate to obtain a nitrophenol.
- the nitrophenol is alkylated with a halogenated sulfhydryl group such as methyl iodide at a suitable temperature to obtain a hydroxy-protected nitrophenol; a hydroxy-protected nitrate
- a halogenated sulfhydryl group such as methyl iodide
- R substituted aryl compound
- R substituted aryl compound under hydrogen atmosphere, palladium/carbon reduction to obtain aryl aniline, aryl aniline in bromine to remove sulfhydryl groups to obtain deprotected aniline.
- the substituted aryl compound is deprotected from the sulfhydryl group in hydrogen bromide to give the deprotected nitro compound.
- the nitro compound is reduced under palladium on carbon under hydrogen to give the deprotected aryl aniline.
- the HPLC test was performed using an Agilent 1200 DAD high pressure liquid chromatograph (Sunfire C18 150> ⁇ 4.6 mm column) and a Waters 2695-2996 high pressure liquid chromatograph (Gimini C18 150 x 4.6 mm column).
- the pressurized hydrogenation reaction uses a Pau 3916EKX hydrogenation apparatus and a clear blue QL type hydrogen generator;
- the microwave reaction uses a CEM Discover-S 908860 microwave reactor;
- the nitrogen atmosphere means that the reaction flask is connected to a nitrogen balloon of about 1 L volume;
- the hydrogen atmosphere means that the reaction flask is connected to a hydrogen balloon of about 1 L volume;
- the solution in the reaction means an aqueous solution
- 5-Aminoindan lg (3.59 g, 27.0 mmol) was dissolved in 20 mL of concentrated hydrochloric acid and stirred for 10 min.
- 10 mL of sodium nitrite solution (1.86 g, 27.0 mmol) was added dropwise, and stirring was continued for 15 minutes in an ice bath.
- the stannous chloride dihydrate (24.4 g, 108.0 mmol) was dissolved in 10 mL of concentrated hydrochloric acid under ice salt bath, and the intermediate solution was added thereto, and the mixture was allowed to react to room temperature for 1.5 hours. The mixture was adjusted to pH 9 with 40% EtOAc EtOAc (EtOAc)EtOAc. Yield: 51.3%.
- 2-Bromo-4-fluoro-phenol 2a (8.0 g, 41.9 mmol) was dissolved in 10 mL of sulfuric acid solution (50%) in an ice salt bath, and sodium nitrate (7.1 g, 83.5 mmol) in 24 mL of sulfuric acid solution was added dropwise. (25%), reacted at room temperature for 1.5 hours. TLC was traced to the disappearance of the starting material, 50 mL of water was added, and the mixture was extracted with ethyl acetate (50 mL ⁇ 2).
- 3-carboxylic acid 3'-Amino-5'-fluoro-2'-hydroxybiphenyl-3-carboxylic acid 2f (296 mg, 1.20 mmol) was dissolved in 10 mL of hydrochloric acid (IN) under ice bath, and 10 mL of sodium nitrite solution was added dropwise. (91 mg, 1.32 mmol), followed by 2-indan-5-yl-5-methyl-2,4-dihydropyrazol-3-one li (257 mg, 1.20 mmol) with sat. sodium bicarbonate The solution was adjusted to pH 8 and added to 10 mL of ethanol and allowed to warm to room temperature overnight.
- 2-Amino-5,6,7,8-tetrahydronaphthalene 3g (3.68 g, 25.0 mmol) was dissolved in 20 mL of concentrated hydrochloric acid and stirred for 10 min.
- 10 mL of sodium nitrite solution (1.72 g, 25.0 mmol) was added dropwise, and stirring was continued for 15 minutes in an ice bath.
- Ethyl 5-iodo-2,4-dimethyl-1H-pyrrole-3-carboxylate 6d (4.1 g, 13.99 mmol) was dissolved in 80 mL of tetrahydrofuran, and methyl 4-methylbenzenesulfonate (2.73) was added. g, 14.69 mmol) and sodium tert-butoxide (2.02 g, 20.99 mmol), and the mixture was stirred at room temperature for 0.5 hour. The reaction was monitored by TLC until the reaction mixture was completed. The reaction mixture was filtered, and the filter cake was washed with THF. The product 5-iodo-1,2,4-trimethyl-1H-pyrrole-3-carboxylic acid ethyl ester 6e (3.8 g, m.p.).
- 5-(3-Amino-2-hydroxyphenyl)-furan-2-carboxylic acid hydrobromide salt 5-(3-amino-2-methoxy-phenyl)-furan-2-carboxylic acid 9b ( 2.79 g, 11.97 mmol) was dissolved in 25 mL of dichloromethane, and boron tribromide (23.9 mL, 2.0 mol/L) was added dropwise and allowed to react at room temperature for 1 hour. TLC was traced to the disappearance of the starting material, 5 mL of methanol was added, and concentrated under reduced pressure.
- the TLC was traced to the disappearance of the starting material, cooled to room temperature, and concentrated under reduced pressure to remove acetic acid.
- the acid in the reaction mixture was neutralized with saturated sodium hydrogen carbonate solution, extracted with ethyl acetate (20 mL ⁇ 3), and the organic phase was combined with saturated sodium chloride solution.
- the organic layer was dried (MgSO4jjjjjjjjjjjj 5-yl)-2,4-dihydropyrazole-3-one 19d (130 mg, light yellow oily liquid). Yield: 13.6%.
- 5-(3-nitro-2-methoxy-5-methylphenyl)-thiophene-2-carboxylic acid 5-(3-nitro-2-methoxy-5-methylphenyl)-thiophene 2-carboxylic acid 24b (0.29 g, 1 mmol) dissolved in To 30 mL of ethyl acetate, 0.06 g of palladium-carbon and cesium formate (0.25 g, 4 mmol) were added, and the mixture was heated and refluxed for 45 minutes. The TLC was traced to the disappearance of the starting material, and the palladium-carbon was removed by filtration.
- 3-Amino-3'-(1 ⁇ -tetrazol-5-yl)-biphenyl-2-ol hydrochloride 8f (188 mg, 0.74 mmol) was dissolved in 4 mL of 2N hydrochloric acid and added dropwise. 1 mL of sodium nitrite solution (57 mg, 0.82 mmol), react for 30 minutes, then add 2-indan-5-yl-5-methyl-2,4-dihydropyrazol-3-one li (159 mg , 0.74 mmol), the pH was adjusted to 8 with saturated sodium bicarbonate, and 0.5 mL of ethanol was added and allowed to react overnight at room temperature.
- 2-(2'-Hydroxy-3'-amino-biphenyl-4-yl)-4,5-dihydro-1H-imidazole 32d (334 mg, 1.11 mmol) was dissolved in hydrochloric acid (3.7 mL). In 1 mol/L), 1.5 mL of sodium nitrite solution (85 mg, 1.22 mmol) was added dropwise, and the reaction was carried out for 20 minutes, followed by the addition of 2-indan-5-yl-5-methyl-2,4-dihydropyridinium. Zylin-3-one li (214 mg, 1 mmol) was adjusted to pH 8 with saturated sodium bicarbonate solution, and 5 mL of ethanol was added and allowed to react overnight at room temperature.
- 3-(4-Bromophenyl)-propionic acid 38a (20.6 g, 90 mmol, ABCR) was added to a 250 mL single-necked flask and dried in vacuo for 20 min.
- Thionyl chloride (20 mL, 276 mmol) was added with stirring and heated to reflux overnight. Most of the solvent was removed under reduced pressure, and 100 mL of dichloromethane was added, and aluminum chloride (24.5 g, 25.8 mmol) was added portionwise with stirring, and a large amount of gas was released, and the reaction was refluxed overnight.
- the reaction mixture was poured into 200 g of crushed ice, and a large amount of solid was precipitated, which was purified by silica gel chromatography. 6-Bromo-indanone 38b (18.34 g, yellow solid). Yield: 96.6%.
- methyl group phenylphosphonium bromide (4.56 g, 12.76 mmol) was dissolved in 25 mL of tetrahydrofuran, and potassium t-butoxide (1.5 g, 13.4 mmol) was added in one portion, and the mixture was stirred at room temperature for 35 minutes.
- 6-Bromo-indan-1 -one 38b (898 mg, 4.25 mmol) was dissolved in 5 mL of tetrahydrofuran, and the solution was added dropwise with stirring. The resulting solution was stirred at room temperature for 1 hour and quenched with 25 mL of water. reaction. The mixture was extracted with chloroform (25 mL EtOAc). EtOAc (EtOAc m. Separation and purification gave the title product 6-bromo-1-methylene-indane 38c (830 mg,yield of yellow oil). Yield: 93.4%. MS nVz (ESl): 208 [M-1] third
- 6-Bromomethylene indan 38c (4.91 g, 23.5 mmol) was dissolved in ethyl acetate, palladium-carbon (0.98 g) was added, and the reaction was carried out for 4 hours at room temperature under a hydrogen atmosphere, and the TLC was traced until the starting material disappeared. The filtrate was filtered, and the filtrate was evaporated tolulululululululululululululululululululululululululululululu
- n-butyllithium (8.6 mL, 13.76 mmol) was added to a three-necked flask, and added to 8 mL of tetrahydrofuran under a dry ice-acetone bath, and 6-bromo-1-methylindane 38d was added with stirring. 1.32 g, 6.26 mmol), the obtained solution was reacted in a dry ice-acetone bath for 2 hours, and a solution of di-tert-butyl azodicarboxylate G.87 g, 8.14 mmol) in 10 mL of tetrahydrofuran was added dropwise, stirring was continued for 30 minutes, and ice was removed.
- Ethyltriphenylphosphonium bromide (14.5 g, 39.1 mmol) was dissolved in 75 mL of tetrahydrofuran, and potassium t-butoxide (5.29 g, 47.3 mmol) was added and stirred at room temperature for 1 hour.
- 6-Bromo-indan-1-one 38b (3.39 g, 18.6 mmol) was dissolved in 25 mL of tetrahydrofuran, and the solution was added dropwise with stirring, and the mixture was stirred at room temperature for 1 hour. TLC was monitored until the reaction of the starting material was complete. The reaction was quenched by the addition of 150 mL of water. The reaction mixture was extracted with dichloromethane (50 mL ⁇ 4). The organic phase was combined and washed with brine (45 mL ⁇ 2) The organic layer was dried over sodium sulfate, filtered and evaporated, evaporated, evaporated, evaporated, evaporated.
- 6-Bromo-1-ethylidene-indan 41a (3.07 g, 13.7 mmol) was dissolved in 80 mL of ethyl acetate at room temperature, and palladium-carbon (0.61 g) was added in a hydrogenation apparatus at 3 atm. After hydrogenation with hydrogen, the mixture was reacted for 5 hours at room temperature, and the reaction of the material was monitored by TLC.
- the di-tert-butyl azodicarboxylate was dissolved in 15 mL of tetrahydrofuran, added dropwise to the above reaction solution, and the mixture was further stirred in a dry ice-acetone bath for 0.5 hour, and the dry ice-acetone bath was removed, and the reaction solution was naturally warmed to room temperature. After stirring for 18 hours, the reaction of the starting material was completely monitored by TLC. To the reaction mixture was added 25 mL of a saturated solution of ammonium chloride to quench the reaction.
- 5-P-Amino-2-hydroxyphenyl)-furan-2-carboxylic acid hydrobromide 9c 333 mg, 1.1 mmol was dissolved in hydrochloric acid (3.7 mL, 1 mol/L) under ice bath. Add 1.5 mL of sodium nitrite solution (85 mg, 1.22 mmol) for 20 minutes, then add 2-(3,3-dimethylindan-5-yl)-5-methyl-2,4-dihydro Pyrazol-3-one 8i (242 mg, 1.0 mmol) was added portionwise sodium bicarbonate (1.4 g, 16.67 mmol) and 3 mL of EtOAc.
- 5-(3-Amino-2-hydroxyphenyl)-furan-2-carboxylic acid hydrobromide 9c (333 mg, 1.1 mmol) was dissolved in hydrochloric acid (3.7 mL, 1 mol/L). Add 1.5 mL of sodium nitrite solution (85 mg, 1.22 mmol) dropwise for 20 minutes, then add 5-methyl-2-(3-methylindan-5-yl)-2,4-dihydropyrazole 3-ketone 38c (228 mg, 1.0 mmol), sodium bicarbonate (1.4 g, 16.67 mmol) and 3 mL of ethanol were added portionwise and allowed to react overnight at room temperature.
- 6-Bromo-indan-1-one 38b (6.02 g, 28.5 mmol) and iodoguanidine (4.4 mL, 70 mmol) were dissolved in 200 mL of THF (dry) and stirred at room temperature for 15 min. g, 68.2 mmol), stirring for 2 hours, TLC was monitored until the reaction of the starting material was completed, 150 mL of water was added to the reaction mixture, and the mixture was extracted with ethyl acetate (150 mL ⁇ 2), and the organic phase was washed with saturated brine. The mixture was dried over sodium sulfate, filtered and evaporated, evaporated, evaporated, evaporated, evaporated,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
- the mixture is adjusted to ppHi to basic with saturated sodium carbonate, extracted with ethyl acetate (50 mL ⁇ 3), combined organic phase, organic Wash with saturated saline, no The aqueous solution was dried over sodium sulfate, and filtered, and then filtered, evaporated, evaporated, evaporated, evaporated.
- 5-(2-methoxy-3-amino-phenyl)-2-methylfuran-3-carboxylic acid 5-(2-methoxy-3-nitrophenyl)-2-methylfuran 3-carboxylic acid 53c (450 mg, 1.62 mmol) was dissolved in methanol, 45 mg of palladium/carbon was added, and the mixture was stirred under reflux for 4 hours under a hydrogen atmosphere, and the residue was evaporated to the residue, and the filtrate was filtered.
- the product 5-(2-methoxy-3-amino-phenyl)-2-methylfuran-3-carboxylic acid 53d (370 mg, white solid).
- reaction solution was sequentially saturated sodium carbonate solution and sodium thiosulfate solution ( 2M) Washed with saturated brine, dried over anhydrous magnesium sulfate, filtered and evaporated to remove the solvent, and the filtrate was concentrated under reduced pressure to give the title product 2,2,2-trichloro-1 -(4-iodo-1 H -pyrrol-2-yl)-acetyl 57c (47 g, yellow solid), Yield: 92%.
- Methyl 4-iodo-1-(toluene-4-sulfonyl)- 1 H-pyrrole-2-carboxylate Methyl 4-iodo-1H-pyrrole-2-carboxylate 57d (25.1 g, 100 mmol)
- triethylamine 30.6 mL, 220 mmol
- 4-dimethylaminopyridine (1.22 g, 10 mmol)
- p-toluenesulfonic acid 21 g, 110 mmol
- reaction mixture was extracted with methylene chloride (50 mL ⁇ 3).
- organic phase was washed with saturated sodium carbonate and brine, dried over anhydrous sodium sulfate 4-iodo-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester 57e (32.5 g, white solid), yield: 80.2%.
- mouse IL-3 (chemicon Catalog no.IL015 )
- Plasmid construction Purchasing the EX-B0010-M02 plasmid (FulenGen) using the QuikChange® Multi Site Directed Mutagenesis Kit (Stratagene) kit according to the TPOR gene sequence provided by Entrez Gene ID: 4325, Refseq: NM-005373 2 point mutation.
- the multi-point mutation primer sequences are: g491a: 5'-gggaacttcagatcagctgggaggagccg-3 ' , g491a- antisense:
- BAF3-TPOR cell line A BaF3 cell line stably expressing a highly functional TPO receptor was constructed. The by expressing human after the 2-point mutant TPO receptor and screening gene neomycin the EX-B0010-M02 plasmid; 25 ⁇ ⁇ transfected with wild-type BaF3 cells (1X10 7), transfection instruments as Electro Square Porator ECM830 (BTX Division of Genetronic, Inc. US), transfection conditions: 250V, 18ms. The BAF3-TPOR stable cell line was obtained by G418 (Gibco, US) screening.
- BAF3-TPOR was cultured in RPMI 1640 (Gibco, US) medium, 10% FB (Gibco, US) S, 800 ng/ml G418, 5 ng/mU rmIL-3 (Chemicon, US).
- Centrifuge the cells by centrifugation Take appropriate amount of cell suspension at 1000 rpm, centrifuge for 5 minutes, discard the supernatant, resuspend the cells with 10 ml of cell culture medium containing no IL3, centrifuge at lOOOOrpm for 5 minutes, discard the supernatant;
- test compound powder was formulated into 10 mM stock solution in DMSO, and diluted to different concentrations with RPM11640: 30 ⁇ , 10 ⁇ , 3 ⁇ , ⁇ , 0.3 ⁇ , 0 ⁇ 1 ⁇ , 0.03 ⁇ , 0 ⁇ 01 ⁇ , 0.003 ⁇ ,
- Rats were used as test animals, and the concentration of the drug in plasma was measured by LC/MS/MS method at different times after administration of Example 1, Example 15 and Example 29 by intragastric administration.
- the pharmacokinetic behavior of the compounds of the invention in rats was investigated and their pharmacokinetic characteristics were evaluated.
- Example 1 Example 15 and Example 29
- the pharmacokinetic parameters of the compounds of the invention are as follows:
- test results showed that each of the compounds was well absorbed after the rats were intragastrically administered with the above compounds of the present invention.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201008616A UA101172C2 (ru) | 2008-01-10 | 2009-01-04 | Бициклозамещенные пиразолоназопроизводные, способ их получения и фармацевтическое применение |
EP09703490.4A EP2236500B1 (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
JP2010541680A JP5441269B2 (ja) | 2008-01-10 | 2009-01-04 | ビシクロ置換ピラゾロン−アゾ誘導体、その調製プロセス及び製薬学的使用 |
AU2009207966A AU2009207966B2 (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
CA2711535A CA2711535C (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
RU2010127786/04A RU2488582C2 (ru) | 2008-01-10 | 2009-01-04 | Бициклозамещенные азопроизводные пиразолона, способ их получения и фармацевтическое применение |
US12/812,119 US8367710B2 (en) | 2008-01-10 | 2009-01-04 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
ES09703490.4T ES2533366T3 (es) | 2008-01-10 | 2009-01-04 | Derivados azoicos de pirazolona biciclo-sustituidos, procedimiento de preparacion y utilización farmacéutica de los mismos |
CN2009800001980A CN101679286B (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
BRPI0907234-9A BRPI0907234B1 (pt) | 2008-01-10 | 2009-01-04 | Derivados de pirazolona-azo biciclo-substituído, seu uso, seu intermediário e seus processos de preparação, composição farmacêutica e deu uso |
MX2010007553A MX2010007553A (es) | 2008-01-10 | 2009-01-04 | Derivados de azopirazolona biciclo-sustituidos, procedimiento de preparacion y uso farmaceutico de los mismos. |
HK10102994.0A HK1134818A1 (en) | 2008-01-10 | 2010-03-23 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
ZA2010/04794A ZA201004794B (en) | 2008-01-10 | 2010-07-07 | Bicyclo-substituted pyrazolon azo derivatives,preparation process and pharmaceutical use thereof |
US13/742,633 US20130123507A1 (en) | 2008-01-10 | 2013-01-16 | Bicyclo-substituted pyrazolon azo derivatives, preparation process and pharmaceutical use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNA2008100003466A CN101481352A (zh) | 2008-01-10 | 2008-01-10 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
CN200810000346.6 | 2008-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009092276A1 true WO2009092276A1 (zh) | 2009-07-30 |
Family
ID=40878665
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000001 WO2009092276A1 (zh) | 2008-01-10 | 2009-01-04 | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 |
Country Status (16)
Country | Link |
---|---|
US (2) | US8367710B2 (zh) |
EP (1) | EP2236500B1 (zh) |
JP (1) | JP5441269B2 (zh) |
KR (1) | KR101556808B1 (zh) |
CN (2) | CN101481352A (zh) |
AU (1) | AU2009207966B2 (zh) |
BR (1) | BRPI0907234B1 (zh) |
CA (1) | CA2711535C (zh) |
ES (1) | ES2533366T3 (zh) |
HK (1) | HK1134818A1 (zh) |
MX (1) | MX2010007553A (zh) |
PT (1) | PT2236500E (zh) |
RU (1) | RU2488582C2 (zh) |
UA (1) | UA101172C2 (zh) |
WO (1) | WO2009092276A1 (zh) |
ZA (1) | ZA201004794B (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010142137A1 (zh) * | 2009-06-11 | 2010-12-16 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,及其制备方法和应用 |
EP2492262A1 (en) * | 2009-10-23 | 2012-08-29 | Nissan Chemical Industries, Ltd. | Fused heterocyclic compound and thrombopoietin receptor activator |
CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
CN106994120A (zh) * | 2016-01-22 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
WO2023143364A1 (zh) * | 2022-01-25 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
CN103360317B (zh) * | 2012-04-11 | 2016-12-14 | 齐鲁制药有限公司 | 双环取代吡唑酮偶氮类衍生物、其制备方法及用途 |
WO2015111085A2 (en) * | 2014-01-27 | 2015-07-30 | Cadila Healthcare Limited | Processes for the preparation of eltrombopag and pharmaceutically acceptable salts, solvates and intermediates thereof |
US9849077B2 (en) | 2014-03-10 | 2017-12-26 | Mary Kay Inc. | Skin lightening compositions |
CN104592033A (zh) * | 2014-12-30 | 2015-05-06 | 杭州和泽医药科技有限公司 | 一种艾曲波帕关键中间体的合成方法 |
AU2017209224A1 (en) * | 2016-01-22 | 2018-07-26 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition comprising bicyclo-substituted pyrazolon azo derivative or salt thereof and preparation method thereof |
WO2018133818A1 (zh) * | 2017-01-19 | 2018-07-26 | 江苏恒瑞医药股份有限公司 | 一种双环取代吡唑酮偶氮类衍生物的制备方法及其中间体 |
CN110028497B (zh) * | 2018-01-11 | 2020-11-17 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素模拟物的乙醇胺盐的结晶形式及制备方法 |
JP2022517211A (ja) * | 2019-01-08 | 2022-03-07 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 二環式置換ピラゾロンアゾ誘導体の投与レジメン |
CN112062699B (zh) * | 2020-11-13 | 2021-02-26 | 苏州开元民生科技股份有限公司 | 一种邻氨基苯硫酚的制备方法 |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040750A1 (en) | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
WO1998025965A2 (en) | 1996-12-11 | 1998-06-18 | Glaxo Group Limited | Peptides and compounds that bind to the thrombopoietin receptor |
WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
WO2000028987A1 (en) | 1998-11-17 | 2000-05-25 | Smithkline Beecham Corporation | Methods of treating thrombocytopenia |
WO2000035446A1 (en) | 1998-12-17 | 2000-06-22 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
WO2000039773A1 (de) | 1998-12-14 | 2000-07-06 | Mannesmann Ag | Verfahren zur übertragung von verkehrsinformationen |
WO2001007423A1 (fr) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Compositions medicamenteuses possedant une activite agoniste de la thrombopoietine |
WO2001017349A1 (en) | 1999-09-10 | 2001-03-15 | Smithkline Beckman Corporation | Thrombopoietin mimetics |
WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
WO2001053267A1 (fr) | 2000-01-24 | 2001-07-26 | Shionogi & Co., Ltd. | Composes presentant un agonisme vis a vis du recepteur de la thrombopoietine |
WO2001089457A2 (en) | 2000-05-25 | 2001-11-29 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
WO2005066115A2 (en) | 2003-12-26 | 2005-07-21 | Allergan, Inc. | Disubstituted chalcone oximes having rarϝ retinoid receptor antagonist activity |
WO2006064957A1 (ja) | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007044982A2 (en) * | 2005-10-13 | 2007-04-19 | Smithkline Beecham Corporation | Methods for the preservation of platelet efficacy during storage |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB775216A (en) * | 1954-02-23 | 1957-05-22 | Sandoz Ltd | Improvements in or relating to monoazo dyestuffs of the benzene-azo-pyrazolone series and their chromium-complex compounds |
GB806709A (en) * | 1955-04-22 | 1958-12-31 | Bayer Ag | Monoazo dyestuffs of the benzene-azo-pyrazolone series and metal complexes thereof |
JPH111477A (ja) | 1997-06-12 | 1999-01-06 | Hokuriku Seiyaku Co Ltd | 1,4−ベンゾジアゼピン誘導体及びその用途 |
DE60031714T2 (de) | 1999-12-06 | 2007-09-06 | Smithkline Beecham Corp. | Thrombopoietin-mimetika |
TWI280128B (en) * | 2002-05-22 | 2007-05-01 | Smithkline Beecham Corp | 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine) |
WO2004096154A2 (en) * | 2003-04-29 | 2004-11-11 | Smithkline Beecham Corporation | Methods for treating degenerative diseases/injuries |
JP4518819B2 (ja) * | 2004-03-17 | 2010-08-04 | 富士フイルム株式会社 | アゾ化合物 |
BRPI0620532A2 (pt) * | 2005-11-23 | 2011-11-16 | Ligand Pharm Inc | compostos e métodos para modular a atividade de trombopoietina |
-
2008
- 2008-01-10 CN CNA2008100003466A patent/CN101481352A/zh active Pending
-
2009
- 2009-01-04 JP JP2010541680A patent/JP5441269B2/ja active Active
- 2009-01-04 CA CA2711535A patent/CA2711535C/en active Active
- 2009-01-04 KR KR1020107017630A patent/KR101556808B1/ko active IP Right Grant
- 2009-01-04 BR BRPI0907234-9A patent/BRPI0907234B1/pt active IP Right Grant
- 2009-01-04 CN CN2009800001980A patent/CN101679286B/zh active Active
- 2009-01-04 UA UAA201008616A patent/UA101172C2/ru unknown
- 2009-01-04 AU AU2009207966A patent/AU2009207966B2/en active Active
- 2009-01-04 WO PCT/CN2009/000001 patent/WO2009092276A1/zh active Application Filing
- 2009-01-04 EP EP09703490.4A patent/EP2236500B1/en active Active
- 2009-01-04 US US12/812,119 patent/US8367710B2/en active Active
- 2009-01-04 ES ES09703490.4T patent/ES2533366T3/es active Active
- 2009-01-04 MX MX2010007553A patent/MX2010007553A/es active IP Right Grant
- 2009-01-04 RU RU2010127786/04A patent/RU2488582C2/ru active
- 2009-01-04 PT PT97034904T patent/PT2236500E/pt unknown
-
2010
- 2010-03-23 HK HK10102994.0A patent/HK1134818A1/xx unknown
- 2010-07-07 ZA ZA2010/04794A patent/ZA201004794B/en unknown
-
2013
- 2013-01-16 US US13/742,633 patent/US20130123507A1/en not_active Abandoned
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040750A1 (en) | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a thrombopoietin receptor |
WO1998025965A2 (en) | 1996-12-11 | 1998-06-18 | Glaxo Group Limited | Peptides and compounds that bind to the thrombopoietin receptor |
WO1999011262A1 (en) | 1997-09-02 | 1999-03-11 | Roche Diagnostics Gmbh | Mpl-receptor ligands, process for their preparation, medicaments containing them and their use for the treatment and prevention of thrombocytopaenia and anaemia |
WO2000028987A1 (en) | 1998-11-17 | 2000-05-25 | Smithkline Beecham Corporation | Methods of treating thrombocytopenia |
WO2000039773A1 (de) | 1998-12-14 | 2000-07-06 | Mannesmann Ag | Verfahren zur übertragung von verkehrsinformationen |
WO2000035446A1 (en) | 1998-12-17 | 2000-06-22 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
WO2001007423A1 (fr) | 1999-07-26 | 2001-02-01 | Shionogi & Co., Ltd. | Compositions medicamenteuses possedant une activite agoniste de la thrombopoietine |
WO2001017349A1 (en) | 1999-09-10 | 2001-03-15 | Smithkline Beckman Corporation | Thrombopoietin mimetics |
WO2001034585A1 (en) | 1999-11-05 | 2001-05-17 | Smithkline Beecham Corporation | Semicarbazone derivatives and their use as thrombopoietin mimetics |
WO2001053267A1 (fr) | 2000-01-24 | 2001-07-26 | Shionogi & Co., Ltd. | Composes presentant un agonisme vis a vis du recepteur de la thrombopoietine |
WO2001089457A2 (en) | 2000-05-25 | 2001-11-29 | Smithkline Beecham Corporation | Thrombopoietin mimetics |
WO2005066115A2 (en) | 2003-12-26 | 2005-07-21 | Allergan, Inc. | Disubstituted chalcone oximes having rarϝ retinoid receptor antagonist activity |
WO2006064957A1 (ja) | 2004-12-14 | 2006-06-22 | Nissan Chemical Industries, Ltd. | アミド化合物及びトロンボポエチンレセプター活性化剤 |
WO2007044982A2 (en) * | 2005-10-13 | 2007-04-19 | Smithkline Beecham Corporation | Methods for the preservation of platelet efficacy during storage |
Non-Patent Citations (10)
Title |
---|
BARLEY ET AL., CELL, vol. 77, 1994, pages 1117 - 1124 |
KAUSHANSKY ET AL., NATURE, vol. 369, 1994, pages 568 - 571 |
KUTER D.I. ET AL., THE ONCOLOGIST, vol. 1, 1996, pages 98 - 106 |
KUTER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 11104 - 11108 |
METCALF, NATURE, vol. 369, 1994, pages 519 - 520 |
SAUVAGE ET AL., NATURE, vol. 369, 1994, pages 533 - 538 |
See also references of EP2236500A4 |
VIGON ET AL., PROC. NAT. ACAD. SCI., vol. 89, 1992, pages 5640 - 5644 |
WENDLING ET AL., NATURE, vol. 369, 1994, pages 571 - 574 |
WENDLING, F., BIOTHERAPY, vol. 10, no. 4, 1998, pages 269 - 77 |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010142137A1 (zh) * | 2009-06-11 | 2010-12-16 | 江苏恒瑞医药股份有限公司 | 双环取代吡唑酮偶氮类衍生物的盐,及其制备方法和应用 |
US8642637B2 (en) | 2009-06-11 | 2014-02-04 | Jiangsu Hengrui Medicine Co., Ltd. | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof |
US9120762B2 (en) | 2009-06-11 | 2015-09-01 | Jiangsu Hengrui Medicine Co., Ltd. | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof |
EP2492262A1 (en) * | 2009-10-23 | 2012-08-29 | Nissan Chemical Industries, Ltd. | Fused heterocyclic compound and thrombopoietin receptor activator |
EP2492262A4 (en) * | 2009-10-23 | 2013-03-20 | Nissan Chemical Ind Ltd | FUSED HETEROCYCLE COMPOUNDS AND THROMBOPOIETIN RECEPTOR ACTIVATOR |
US8889732B2 (en) | 2009-10-23 | 2014-11-18 | Nissan Chemical Industries, Ltd. | Fused heterocyclic compounds and thrombopoietin receptor activators |
JP5704073B2 (ja) * | 2009-10-23 | 2015-04-22 | 日産化学工業株式会社 | 縮環へテロ環化合物及びトロンボポエチンレセプター活性化剤 |
CN103724206A (zh) * | 2014-01-17 | 2014-04-16 | 青岛农业大学 | 化合物2-溴-4-氟-6-硝基苯酚的制备方法和农用生物活性 |
CN106994120A (zh) * | 2016-01-22 | 2017-08-01 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
CN106994120B (zh) * | 2016-01-22 | 2021-05-14 | 江苏恒瑞医药股份有限公司 | 一种含有双环取代吡唑酮偶氮类衍生物或其盐的药物组合物及其制备方法 |
WO2022228551A1 (zh) * | 2021-04-30 | 2022-11-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
WO2023143364A1 (zh) * | 2022-01-25 | 2023-08-03 | 江苏恒瑞医药股份有限公司 | 一种血小板生成素受体激动剂的给药方案 |
Also Published As
Publication number | Publication date |
---|---|
EP2236500A1 (en) | 2010-10-06 |
ES2533366T3 (es) | 2015-04-09 |
CA2711535A1 (en) | 2009-07-30 |
JP2011509263A (ja) | 2011-03-24 |
MX2010007553A (es) | 2010-10-04 |
UA101172C2 (ru) | 2013-03-11 |
RU2488582C2 (ru) | 2013-07-27 |
CN101679286A (zh) | 2010-03-24 |
RU2010127786A (ru) | 2012-02-20 |
US8367710B2 (en) | 2013-02-05 |
JP5441269B2 (ja) | 2014-03-12 |
EP2236500B1 (en) | 2014-12-24 |
US20100316601A1 (en) | 2010-12-16 |
KR101556808B1 (ko) | 2015-10-01 |
CN101679286B (zh) | 2011-06-08 |
KR20100120141A (ko) | 2010-11-12 |
CA2711535C (en) | 2015-12-15 |
ZA201004794B (en) | 2011-09-28 |
AU2009207966A1 (en) | 2009-07-30 |
BRPI0907234A2 (pt) | 2020-08-04 |
BRPI0907234B1 (pt) | 2021-08-10 |
PT2236500E (pt) | 2015-04-07 |
US20130123507A1 (en) | 2013-05-16 |
HK1134818A1 (en) | 2010-05-14 |
AU2009207966B2 (en) | 2013-03-21 |
CN101481352A (zh) | 2009-07-15 |
EP2236500A4 (en) | 2012-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009092276A1 (zh) | 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用 | |
JP2011509263A5 (zh) | ||
US6380238B1 (en) | Indoline derivatives as 5-HT2B and or 5-HTC receptor ligands | |
DK2276732T3 (en) | Novel østrogenreceptorligander | |
JP5237810B2 (ja) | 5−HT2C受容体アゴニストとしての6−置換された2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン | |
NZ512830A (en) | Triazole compounds with dopamine-D3-receptor affinity | |
JP2007514690A (ja) | ヒスタミンh3アンタゴニストとしてのベンズアゼピン誘導体 | |
MX2007001106A (es) | Derivados de piperazina utiles para el tratamiento de trastornos gastrointestinales. | |
WO2022135442A1 (zh) | Cdk2抑制剂及其制备方法 | |
WO2019062328A1 (zh) | 苯胺取代的1,2-二氢吡咯并[3,4-c]吡啶/嘧啶-3-酮衍生物及用途 | |
WO2006051851A1 (ja) | 2,3,4,5-テトラヒドロ-1h-1,5-ベンゾジアゼピン誘導体、及び、医薬組成物 | |
WO2003095430A1 (en) | Substituted pyrazolyl compounds for the treatment of inflammation | |
US8071589B2 (en) | Dihydrobenzoindazoles | |
WO2009103218A1 (zh) | 亚乙基肼酰胺类衍生物、其制备方法及其在医药上的应用 | |
JP2002543187A (ja) | α−1Aアドレナリン受容体リガンドとしてのイミダゾリン誘導体 | |
EP2459551B1 (en) | Dihydrobenzoindazoles | |
TWI437985B (zh) | 雙環取代吡唑酮偶氮類衍生物、其製備方法及其在醫藥上的應用 | |
KR102406246B1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
Dabak et al. | Synthesis of 1-vinyl 1, 2, 3-triazole derivatives | |
WO2024099226A1 (zh) | 含苯联杂芳基的二氢喋啶酮衍生物及其用途 | |
CN117886799A (zh) | 一类靶向降解GSK-3β的蛋白降解靶向嵌合体化合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980000198.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09703490 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010541680 Country of ref document: JP Ref document number: 2009207966 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2711535 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12812119 Country of ref document: US Ref document number: 4949/DELNP/2010 Country of ref document: IN Ref document number: 2009703490 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2010/007553 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2009207966 Country of ref document: AU Date of ref document: 20090104 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107017630 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010127786 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0907234 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100712 |